At the CIIE, JD Health signed agreements with more than 20 brands including Pfizer and Merck; in the first three quarters, it launched more than 100 new drugs, and JD HEALTH (06618) remains firmly the largest pharmaceutical retail platform in China.

On November 5, the 9th China International Import Expo opened in Shanghai. According to Cao Dong, SEC member of JD Group and CEO of JD HEALTH, during the CIIE, JD HEALTH (06618) will sign centralized agreements with more than 20 global pharmaceutical and health brands, including Pfizer, Merck, Novo, Centrum Caltrate, Jamieson, Omron, and Siemens, covering pharmaceuticals, nutrition and health supplements, and medical devices. Currently, JD HEALTH has established deep partnerships with 50 of the world's top multinational pharmaceutical companies. At this CIIE, JD HEALTH also launched a medical tourism business, providing international patients with one-stop services for receiving medical treatment in China. It is reported that by revenue scale, JD HEALTH has firmly remained China's largest pharmaceutical retail platform for many consecutive years, and its pharmaceutical retail scale has long ranked first in the industry. As of the first three quarters of 2026, JD HEALTH had launched more than 100 new drugs online for the first time, exceeding the total for the whole of last year. Buy quality global medicines on JD, and cooperation goes beyond simply listing products At this CIIE, JD HEALTH's cooperation with pharmaceutical companies extends from new product debuts and new product exclusive distribution to patient management and AI innovation. Many pharmaceutical companies have cooperated with JD HEALTH for more than 10 years, and this year's CIIE builds further on existing cooperation. Judging from progress since 2026, cooperation between multinational pharmaceutical companies and JD HEALTH has been deepening. In terms of launch speed, Novartis's remibrutinib tablets had their global online debut in March, Pfizer's Xianweiying had its global online debut on JD HEALTH in April, and Leo Pharma's Enstilar had its global online debut in August... Takeda's Ozeyue had its exclusive global online debut on October 15, and after the debut, patients can conduct online follow-up visits, renew prescriptions, and purchase medicines through JD Internet Hospital. (On November 5, JD HEALTH made its CIIE debut and jointly launched the "White Paper on Women's Metabolic Health in China" project with Pfizer) In terms of cooperation results, sales of relevant Boehringer Ingelheim products on JD HEALTH grew by nearly 20% year on year from January to September 2026; in the tenth anniversary of cooperation with Haleon, the transaction value of relevant products on JD channels in 2025 grew by more than 50% year on year, with cumulative precise reach to more than 5 million pain sufferers; Organon's self-operated channel transaction value grew by 42% year on year; and as of September 30, sales of relevant AstraZeneca products on JD's self-operated channels grew by 51.1% year on year. What pharmaceutical companies value is JD HEALTH's omnichannel supply chain, internet medical services and compliance capabilities, as well as its ability to implement AI across all scenarios. It is reported that by revenue scale, JD HEALTH has firmly remained China's largest pharmaceutical retail platform for many consecutive years. As of the first three quarters of 2026, JD HEALTH had launched more than 100 new drugs online for the first time, exceeding the total for the whole of last year, covering fields such as oncology, dermatology, chronic diseases, GLP-1 weight-loss and metabolic treatments, and women's health. JD HEALTH's view of a "debut" is this: a debut is not a launch event, but a fulfillment order. After the launch event ends and the trending topic passes, whether the drug can be prescribed, obtained at the pharmacy, and connected in follow-up care is the true second half of a debut. Buying quality global medicines on JD means enabling these global medicines to enter China as quickly as possible and allowing patients in need to use them as soon as possible. Medical tourism: global medicines enter China, and China's quality medical services serve the world During the CIIE, JD HEALTH officially launched its "medical tourism" business, providing overseas patients with one-stop services for receiving medical treatment in China. It is reported that JoyDoctor's domestic iOS version, overseas iOS version, and overseas Google version have all been launched, and service cases already exist in categories such as health checkups, dentistry, rare diseases, and pre-surgical dermatology outpatient consultations. The first batch focuses on serving countries such as Qatar, the UAE, Kazakhstan, and Indonesia, covering the Middle East, Central Asia, Southeast Asia, and Mongolia. It is understood that overseas patients are unfamiliar with the procedures of Chinese hospitals. Medical tourism helps patients connect with hospitals and doctors, arrange appointments and itineraries, assist with visas, provide accompanying interpretation and medical coordination upon arrival in China, and offer follow-up after returning home. Partner hospitals cover multiple top medical institutions in Beijing, Shanghai, Guangzhou, and other places. Together with self-operated institutions such as JD Health Checkup, JD Traditional Chinese Medicine Bone Setting, and JD Medical Aesthetics, they undertake health travel and medical service needs, with a fulfillment network spanning the country. The state has clearly stated that it will expand inbound health consumption and build an international medical tourism brand, and JD HEALTH's medical tourism service is precisely in line with this policy direction. JD HEALTH stated that this is an open attempt to bring China's high-quality medical and health service capabilities to the world. At present, the focus is on serving the categories that have already been implemented well, and partner hospitals and self-operated institutions will be connected gradually according to service capacity. "Global debuts in China, and China debuts on JD, is not something shouted out. It is achieved by launching new drugs one by one, so that patients in need can access them and use them well," said a relevant person in charge of JD HEALTH. In addition to accelerating the entry of quality global medicines, nutrition products, and devices into China, China's quality hospitals, doctors, and services are also serving patients worldwide, enabling those in need to find suitable medical resources more quickly.